Evidence map›Paper›PMID 37631910›Full record

ArticleVaccines2023

Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination.

Antonella Zizza, Raffaella Sedile, Francesco Bagordo, Alessandra Panico, Marcello Guido, Tiziana Grassi, Federico Banchelli, Pierfrancesco Grima

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Antonella ZizzaInstitute of Clinical Physiology, National Research Council, 73100 Lecce, Italy.ORCID 0000-0001-5598-8499
Raffaella SedileInstitute of Clinical Physiology, National Research Council, 73100 Lecce, Italy.
Francesco BagordoDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70121 Bari, Italy.
Alessandra PanicoDepartment of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy.ORCID 0000-0002-1876-7184
Marcello GuidoDepartment of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy.ORCID 0000-0002-7907-2677
Tiziana GrassiDepartment of Biological and Environmental Science and Technology, University of Salento, 73100 Lecce, Italy.ORCID 0000-0003-1200-2778
Federico BanchelliDepartment of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
Pierfrancesco GrimaInfectious Diseases Unit, Vito Fazzi Hospital, 73100 Lecce, Italy.ORCID 0000-0003-4397-9522
University of Salento · ITNational Research Council · ITOspedale Vito Fazzi · ITUniversity of Bari Aldo Moro · ITUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with COVID-19 can develop different forms of the illness with more or less severe symptoms. A 2-year retrospective cohort study was conducted to evaluate the factors associated with the development of pneumonia in patients hospitalized with COVID-19 from March 2020 to February 2022. A total of 385 patients (59.0% males) with a mean age of 69.0 ± 16.0 years were included. At hospital admission, 318 patients (82.6%) reported one or more comorbidities, namely 201 (52.2%) subjects were affected by hypertension, 98 (25.5%) type 2 diabetes, 84 (21.8%) obesity, 36 (9.4%) cancer, and 14 (3.6%) suffered from kidney disease and were being treated with dialysis, and 76 (19.7%) resulted in being vaccinated with a higher prevalence of BNT162b2 vaccine (15.0%). Pneumonia was diagnosed in 276 (71.7%) patients. Multivariate regression analysis showed that pneumonia in COVID-19 patients was positively associated with type 2 diabetes (OR 1.81; 95% CI 1.00-3.27), obesity (OR 2.52; 95% CI 1.27-4.98), and negatively with hypertension (OR 0.58; 95% CI 0.35-0.96). Vaccination against SARS-CoV-2 resulted in a strongly protective factor against the development of pneumonia in COVID-19 patients (OR 0.49; 95% CI 0.28-0.85).

Indexed as

comorbiditiesCOVID-19pneumoniaSARS-CoV-2vaccination

Identifiers

PMID37631910
PMCPMC10458032
OpenAlexW4385650485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.